Skip to main
  1. Stocks
  2. CAMP4 Therapeutics Corp
  3. Forecast
CAMP

CAMP Stock Forecast & Price Target

CAMP Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Camp4 Therapeutics is attractive fundamentally because CMP-002 targets SYNGAP1, a rare genetic neurological disorder with ~11K U.S. patients, no approved drugs, and severe unmet needs in cognition, communication, seizures, and adaptive function. Its ASO-based RAP platform is clinically validated, programmable, and designed to restore SYNGAP1 expression without altering DNA, while preclinical data show dose-dependent mRNA normalization, near wild-type protein restoration, and seizure reduction in humanized models plus broad brain exposure in NHPs. Financially, the company ended 2Q:26 with $86 million in cash, added $50 million in financing, and is estimated to have ~$133 million pro forma cash to fund operations through YE:28, supporting an important Phase I/II study expected to start in 2H:26.

Bears say

Camp4 Therapeutics is burdened by a weak fundamental setup because it remains a development-stage company with no revenue-producing products, no anticipated profitability for several years, and a continuing cash burn that likely forces additional debt or equity financing. The need for long and expensive clinical development, combined with the risk of dilutive capital raises, restrictive covenants, and uncertain access to funding under market-dependent conditions, makes execution and shareholder returns highly uncertain. Competitive pressure is also severe, as stronger SYNGAP1 programs from better-resourced rivals raise the bar for success, while clinical, regulatory, and intellectual property risks could further delay or derail CMP-002, CMP-CPS-001, and CMP-SYNGAP.

CAMP has been analyzed by 8 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CAMP4 Therapeutics Corp and is not a guaranteed prediction by Public.com or investment advice.

CAMP Analyst Forecast & Price Prediction

Get the latest CAMP stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in CAMP

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CAMP4 Therapeutics Corp (CAMP) Forecast

Analysts have given CAMP a Buy based on their latest research and market trends.

According to 8 analysts, CAMP has a Buy consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.88, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.88, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CAMP4 Therapeutics Corp (CAMP)


CAMP Analyst Forecast & Price Prediction

Get the latest CAMP stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in CAMP

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover CAMP stock data and trends